Medicine and Dentistry
Clostridium Difficile Infection
100%
Probiotic Agent
100%
Adverse Event
28%
Placebo
14%
Subgroup Analysis
14%
Peptoclostridium difficile
14%
Antibiotics
9%
High Risk Population
9%
Random Effects Model
9%
Prophylaxis
4%
Randomized Controlled Trial
4%
Infection Rate
4%
Meta-Analysis
4%
Systematic Review
4%
Pathogen
4%
Outpatient
4%
Pediatrics
4%
Drug Megadose
4%
Risk Reduction
4%
Post-Hoc Analysis
4%
Inflammatory Bowel Disease
4%
Nausea
4%
Numbers Needed to Treat
4%
Antibiotic-Associated Diarrhea
4%
Taste Disorder
4%
Flatulence
4%
Psychology
Random Effects Model
100%
Systematic Review
50%
Meta-Analysis
50%
Main Result
50%
Practice Guideline
50%
Eligibility Requirement
50%
Pharmacology, Toxicology and Pharmaceutical Science
Clostridium Difficile Infection
100%
Probiotic Agent
100%
Adverse Event
28%
Placebo
14%
Peptoclostridium difficile
14%
Random Effects Model
9%
Antibiotic Agent
9%
Infection Rate
4%
Randomized Controlled Trial
4%
Infectious Agent
4%
Inflammatory Bowel Disease
4%
Nausea
4%
Intestine Flora
4%
Number Needed to Treat
4%
Flatulence
4%
Antibiotic Associated Diarrhea
4%
Taste Disorder
4%